| Electrocortical and autonomic alteration by administration of a pleasant and an unpleasant odor P Brauchli, PB Rüegg, F Etzweiler, H Zeier Chemical senses 20 (5), 505-515, 1995 | 234 | 1995 |
| Phase II study of capecitabine and oxaliplatin in first-and second-line treatment of advanced or metastatic colorectal cancer MM Borner, D Dietrich, R Stupp, R Morant, H Honegger, M Wernli, ... Journal of clinical oncology 20 (7), 1759-1766, 2002 | 216 | 2002 |
| Effects of work demands on immunoglobulin A and cortisol in air traffic controllers H Zeier, P Brauchli, HI Joller-Jemelka Biological psychology 42 (3), 413-423, 1996 | 209 | 1996 |
| Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non … D Koeberle, DC Betticher, R Von Moos, D Dietrich, P Brauchli, ... Annals of oncology 26 (4), 709-714, 2015 | 149 | 2015 |
| A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and … MM Borner, J Bernhard, D Dietrich, R Popescu, M Wernli, P Saletti, ... Annals of oncology 16 (2), 282-288, 2005 | 134 | 2005 |
| Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial … T Ruhstaller, M Pless, D Dietrich, H Kranzbuehler, R von Moos, ... Journal of clinical oncology 29 (6), 626-631, 2011 | 133 | 2011 |
| Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated endometrial cancers: new candidates for checkpoint blockade immunotherapy? P Gargiulo, C Della Pepa, S Berardi, D Califano, S Scala, L Buonaguro, ... Cancer treatment reviews 48, 61-68, 2016 | 128 | 2016 |
| The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster … F Strasser, D Blum, R Von Moos, R Cathomas, K Ribi, S Aebi, D Betticher, ... Annals of Oncology 27 (2), 324-332, 2016 | 117 | 2016 |
| A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma C Renner, PL Zinzani, R Gressin, D Klingbiel, PY Dietrich, F Hitz, ... Haematologica 97 (7), 1085, 2012 | 110 | 2012 |
| Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III … T Ruhstaller, P Thuss-Patience, S Hayoz, S Schacher, JR Knorrenschild, ... Annals of oncology 29 (6), 1386-1393, 2018 | 89 | 2018 |
| Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation KJ Dedes, K Matter-Walstra, M Schwenkglenks, BC Pestalozzi, D Fink, ... European Journal of Cancer 45 (8), 1397-1406, 2009 | 82 | 2009 |
| Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02) B Klaeser, E Nitzsche, JC Schuller, D Köberle, L Widmer, S Balmer-Majno, ... Oncology Research and Treatment 32 (12), 724-730, 2009 | 66 | 2009 |
| Electrocortical, autonomic, and subjective responses to rhythmic audio-visual stimulation P Brauchli, CM Michel, H Zeier International Journal of Psychophysiology 19 (1), 53-66, 1995 | 58 | 1995 |
| Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07) R Cathomas, C Rothermundt, D Klingbiel, L Bubendorf, R Jaggi, ... Clinical cancer research 18 (21), 6049-6057, 2012 | 56 | 2012 |
| Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05) M Jörger, F Baty, M Früh, C Droege, RA Stahel, DC Betticher, R von Moos, ... Lung Cancer 85 (2), 306-313, 2014 | 52 | 2014 |
| Preoperative versus postoperative docetaxel–cisplatin–fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 … N Fazio, R Biffi, R Maibach, S Hayoz, S Thierstein, P Brauchli, J Bernhard, ... Annals of Oncology 27 (4), 668-673, 2016 | 49 | 2016 |
| Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a … C Jost, J Binek, JC Schuller, P Bauerfeind, U Metzger, B Werth, J Knuchel, ... Gastrointestinal endoscopy 71 (7), 1114-1121, 2010 | 49 | 2010 |
| Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07) K Zaman, B Thürlimann, J Huober, A Schönenberger, O Pagani, J Lüthi, ... Annals of oncology 23 (6), 1474-1481, 2012 | 48 | 2012 |
| Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: A randomized phase III noninferiority … D Koeberle, DC Betticher, R Von Moos, D Dietrich, P Brauchli, ... Journal of Clinical Oncology 31 (15_suppl), 3503-3503, 2013 | 47 | 2013 |
| Recurrence patterns and long-term results after induction chemotherapy, chemoradiotherapy, and curative surgery in patients with locally advanced esophageal cancer T Steffen, D Dietrich, A Schnider, C Kettelhack, O Huber, WR Marti, ... Annals of surgery 269 (1), 83-87, 2019 | 42 | 2019 |
